Market Access News | pharmaphorum

News

Dupixent nears EU approval for COPD, as FDA delays

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chr

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Lilly’s Retevmo cleared for RET-positive child cancers

The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class av

News

COVID-19 vaccinations now ‘alarmingly low’ in Europe

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.

News

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi

News

Asahi Kasei makes $1.1bn bid to buy Calliditas

Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.

Dupixent nears EU approval for COPD, as FDA delays

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Lilly’s Retevmo cleared for RET-positive child cancers

COVID-19 vaccinations now ‘alarmingly low’ in Europe

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

Asahi Kasei makes $1.1bn bid to buy Calliditas

Zydus follows Lupin with Myrbetriq settlement deal

How to meet your physicians where they are online

News

Editor's Picks